Delenex Announces New Clinical Data
News Apr 16, 2015
Delenex Therapeutics AG has announced new clinical data of its lead program DLX105. DLX105 is a PENTRA®Body targeting TNFα for the treatment of inflammatory skin and autoimmune disorders.
In a double-blind, parallel-group, placebo-controlled phase 2 study involving 24 healthy volunteers, the pharmacokinetics of three dose levels of i.v. DLX105 were studied. A high volume of distribution was observed indicating effective and fast tissue distribution making it a promising candidate to treat patients with flaring inflammatory diseases. A total of 6 patients with flaring Behçet’s disease were subsequently enrolled in an open-label study.
Each patient received a single dose of 10 mg/kg DLX105 i.v.. Rapid resolution of cutaneous and mucosal eruptions typical for flaring Behçet’s disease was observed. Within a week post injection of DLX105 signs and symptoms of the preceding flare had almost completely disappeared confirming the rapid and efficient therapeutic activity of a single injection of DLX105 in those inflamed lesions. The clinical response was evident up to 4 weeks post treatment.
“The fast and almost complete resolution of erythemata nodosa following a single infusion of DLX105 in one of our patients was particularly remarkable. The patient suffered from those difficult-to-treat skin nodules for already 5 years and all previous systemic therapies were ineffective,” said Theodoros Xenitidis, MD, University of Tübingen and investigator in this study. Also Ina Kötter, MD, investigator from Hamburg, confirmed substantial improvement of clinical symptoms of her treated patients.
“As the applied single dose of DLX105 showed clinical activity up to 4 weeks, we have good evidence to believe that high biological activity associated with excellent tissue penetration into the inflamed lesions makes a difference to these patients. In addition, treatment was well tolerated,” commented Thomas Jung, MD, Chief Medical Officer at Delenex. “The data add substantial evidence to our proof-of-concept demonstrating the value of small and highly potent PENTRA®Bodies for inflamed skin and autoimmune disorders,” adds Thomas Hecht, MD, Executive Chairman of Delenex.
Study Reveals How MRSA Infection Compromises Lymphatic FunctionNews
Infections of the skin or other soft tissues with the hard-to-treat MRSA bacteria appear to permanently compromise the lymphatic system, which is crucial to immune system function. Investigators describe how MRSA infection impairs the ability of lymphatic vessels to pump lymphatic fluid to lymph nodes in mouse models, which may contribute to the frequent recurrences of MRSA infection experienced by patients.
Possible Biomarker to Identify Who Would Benefit from ImmunotherapyNews
While immunotherapy has made a big impact on cancer treatment, the fact remains that only about a quarter of patients respond to these treatments. In a new study, researchers examined tissue samples from melanoma and ovarian cancer patients treated with immunotherapies and found a link between the percentage of antigen-presenting cells expressing PD-L1 and an objective clinical response to treatment.READ MORE
Fight Against Cancer: Drug Combination Helps Kickstart the Immune SystemNews
Scientists from King's College London have found a way to boost the immune system to help it fight back against cancer.
The breakthrough involves the first ever use of a combination of chemotherapy and a drug being trialled as a treatment for neonatal jaundice, that together help kick start the body's natural defences.